100% secure
Email this product page
Print this page

Low Density Lipoprotein

Low Density Lipoprotein gallery image 1

Published customer image:
Oxidized native Human Low Density Lipoprotein used to treat Human vascular endothelial cells (HUVECs) in vitro prior to analysis by western blotting.
Image caption:
sTREM-1 protects HUVEC from TNF-α and oxLDL in vitro. (A) HUVECs were pretreated with sTREM-1 at 0.1, 1.0, 10mg/mL or not for 0.5 hour, TNF-α (10 ng/mL) was then added. Cells were cultured for another 24 hours and harvested for Western blotting. Data are means±SD of 6 independent experiments. *P<0.05, **P<0.01, TNF-α +/sTREM-1=0 versus all other values. (B) HUVECs were pretreated with sTREM-1 at 0.1, 1.0, 10mg/mL or not for 0.5 hour, oxLDL (50mg/mL) was then added. Cells were cultured for another 24 hours and harvested for Western blotting. Data are means±SD of 6 independent experiments. *P<0.05, **P<0.01, oxLDL +/sTREM-1=0 versus all other values. HUVEC=human umbilical vein endothelial cell, oxLDL=oxidized low-density lipoprotein, TNF-a=tumor necrosis factor-a, sTREM-1=soluble triggering receptor expressed on myeloid cells 1.

From: Dai D, Xiong W, Fan Q, Wang H, Chen Q, Shen W, Zhang R, Ding F, Lu L, Tao R.
Association of decreased serum sTREM-1 level with the severity of coronary artery disease: Inhibitory effect of sTREM-1 on TNF-a- and oxLDL-induced inflammatory reactions in endothelial cells.
Medicine (Baltimore). 2016 Sep;95(37):e4693.

  • Low Density Lipoprotein thumbnail image 1
  • Native Human Low Density Lipoprotein (Oxidized)
(Rated 0.0 out of 5 based on 0 customer reviews)
  • Product Type
    Purified Protein
1 Formats Available
    Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
    5685-3557FNdatasheet pdfdatasheet pdf2 mg
    Secondary Antibodies
    Negative Isotype Controls
    Useful Reagents
    Positive Controls
    Histology Controls
    More Images
    • Native oxidized Human Low Density LipoproteinLow density lipoprotein is provided, purified from human plasma in liquid form. (LDL) oxidative modification is one of the major processes involved in atherosclerosis along with other degenerative disorders. Oxidised LDL is preferentially accumulated by macrophages which become so called "foam cells" within the atheromatous plaque and contributes to the accumulation of cholesterol, typical of atherosclerosis.
    • Intended Use
    • Target Species
    • Product Form
      Purified oxidised LDL from human plasma - liquid
    • Reconstitution
    • Preparation
      LDL is purified to homogeneity by ultra-centrifugation. Oxidised using 20 µM cupric sulphate in PBS at 37ºC for 24 hours. Oxidation is terminated with excess EDTA. The level of oxidation is measured using TBARS (Thiobarbituric acid reactive substances) determination using a Malondialdehyde (MDA) standard. The level of oxidation is batch specific and available on request.
    • Preservative Stabilisers
      0.3 mM EDTA
    • Purity
    • Approx. Protein Concentrations
      Total protein concentration 2.0 mg/ml
    • Reagents In The Kit
    • Preparing The Antibody
    • Test Principle
    • Buffer Solution
      Phosphate buffered saline
    • Storage
      Store at +4oC. DO NOT FREEZE.
      This product should be stored undiluted.
    • Shelf Life
      This product is stable for approximately 4 weeks when handled aseptically and stored at 4ºC. Please see label for expiry date.
    • Acknowledgements
    • Regulatory
      For research purposes only
    • This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

    • Application NameYesNoMin DilutionMax Dilution
      Functional Assays

    • Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.
    • Technical Advice
    • Recommended Protocol
    • ELISA
    • Immunohistology
    • Histology Positive Control Tissue
    • Immunofluorescence
    • Western Blotting
    • Instructions For Use

    Additional Low Density Lipoprotein Formats

    Formats Applications Sizes available
    Low Density Lipoprotein : Purified FN 2 mg
    • Copyright © 2016 Bio-Rad

    Recommended Secondary Antibody

      Recommended Negative Isotype Control

        Useful Reagents

          Recommended Positive Controls

            Histology Controls

                • Product Images

                • Low Density Lipoprotein thumbnail image 1


              Write your review

              You may also be interested in...